Kairos Pharma to Hold Annual Shareholders Meeting Virtually
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KAPA?
Source: Newsfilter
- Annual Meeting Announcement: Kairos Pharma, Ltd. has announced that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on June 29, 2026, with meeting materials to be mailed to shareholders post-filing with the SEC, ensuring compliance and transparency.
- Audit Report Emphasis: The financial statements included in the Annual Report for the year ended December 31, 2025, contain an audit report from an Independent Registered Public Accounting Firm, emphasizing that the statements were prepared under the assumption of the company's ongoing viability, reflecting confidence in future operations.
- Clinical Trial Developments: The company's lead candidate, ENV105, is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, aimed at addressing significant unmet medical needs, showcasing the company's innovative potential in oncology therapeutics.
- Cautionary Forward-Looking Statements: The press release includes cautionary forward-looking statements, alerting investors to potential risks and uncertainties, emphasizing that actual results may differ materially from expectations, reflecting the company's cautious approach to future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KAPA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KAPA
Wall Street analysts forecast KAPA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.555
Low
4.00
Averages
4.00
High
4.00
Current: 0.555
Low
4.00
Averages
4.00
High
4.00
No data
About KAPA
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kairos Pharma to Hold Annual Shareholders Meeting Virtually
- Annual Meeting Announcement: Kairos Pharma, Ltd. has announced that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on June 29, 2026, with meeting materials to be mailed to shareholders post-filing with the SEC, ensuring compliance and transparency.
- Audit Report Emphasis: The financial statements included in the Annual Report for the year ended December 31, 2025, contain an audit report from an Independent Registered Public Accounting Firm, emphasizing that the statements were prepared under the assumption of the company's ongoing viability, reflecting confidence in future operations.
- Clinical Trial Developments: The company's lead candidate, ENV105, is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, aimed at addressing significant unmet medical needs, showcasing the company's innovative potential in oncology therapeutics.
- Cautionary Forward-Looking Statements: The press release includes cautionary forward-looking statements, alerting investors to potential risks and uncertainties, emphasizing that actual results may differ materially from expectations, reflecting the company's cautious approach to future developments.
See More
Schall Law Firm Investigates Kairos Pharma for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Kairos Pharma, focusing on potential violations of securities laws, including false or misleading statements that may affect investor rights.
- Investor Rights Protection: This investigation aims to protect investors, particularly those who have suffered losses due to the company's lack of transparency, by providing legal support to uphold their rights.
- Legal Consultation Services: Schall encourages affected shareholders to contact them for free legal consultations, helping investors understand their rights and possible legal avenues.
- Global Investor Representation: As a firm specializing in securities class action lawsuits and shareholder rights litigation, Schall Law Firm represents investors worldwide, committed to safeguarding their legitimate interests.
See More
Kairos Pharma Acquires CL-273 to Expand Oncology Pipeline
- Significant Market Opportunity: Kairos Pharma's acquisition of CL-273 targets a projected $16.2 billion EGFR-mutant lung cancer market by 2026, indicating a strategic positioning in the rapidly growing oncology therapeutics sector.
- Innovative Technical Advantage: CL-273 is an AI-designed pan-EGFR inhibitor specifically engineered for EGFR-mutant non-small cell lung cancer, expected to become a best-in-class asset addressing the urgent need for therapies against resistant mutations.
- Strengthened Partnerships: The collaboration with Celyn Therapeutics, backed by OrbiMed, enhances Kairos Pharma's research capabilities and is anticipated to accelerate the clinical development timeline for new therapies.
- Leadership Confidence: CEO John Yu stated that this acquisition is expected to be value-accretive, reflecting Kairos Pharma's long-term commitment and competitive edge in the oncology market.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Kairos Pharma to Acquire Oncology Assets from Celyn Therapeutics
- Acquisition Agreement: Kairos Pharma Ltd. announced the signing of a term sheet to acquire two clinical oncology assets from Celyn Therapeutics, specifically CL-273 and CL-741, aimed at addressing non-small cell lung cancer (NSCLC), one of the most prevalent and challenging cancers globally.
- Significant Market Potential: The market for kinase inhibitors in cancer treatment is projected to reach $60.7 billion by 2025, with EGFR inhibitors accounting for 32.5%, while CL-273 targets the EGFR-mutated lung cancer segment, expected to be valued at $16.2 billion by 2026, indicating substantial market opportunities.
- Innovative Treatment Strategy: Kairos aims to combine a pan-EGFR inhibitor with a c-MET inhibitor to overcome drug resistance in NSCLC, deepening tumor responses and extending progression-free survival, a strategy that aligns with AstraZeneca's SAVANNAH trial, underscoring its scientific rationale.
- Utilization of Clinical Infrastructure: CEO John Yu stated that if the acquisition is completed, it would significantly expand the company's pipeline and leverage the clinical infrastructure at Cedars-Sinai Medical Center to accelerate Phase 1 and Phase 2 studies, further solidifying its competitive position in the multi-billion-dollar lung cancer market.
See More
Kairos Pharma Wins 2025 Clinical Trials Arena R&D Award for Advanced Prostate Cancer
- Award Recognition: Kairos Pharma has been awarded the 2025 Clinical Trials Arena R&D Award for its innovative therapy ENV-105 in metastatic castration-resistant prostate cancer, highlighting its leadership in cancer treatment.
- Clinical Trial Results: In the Phase 2 trial of ENV-105 combined with apalutamide, 86% of patients showed clinical benefit, with all responders remaining progression-free for at least four months and some beyond one year, indicating the therapy's potential in patients with limited options.
- Targeted Therapy Strategy: ENV-105, as the first CD105-targeting monoclonal antibody, aims to overcome resistance following standard hormone treatments, emphasizing Kairos Pharma's innovative approach and scientific rigor in cancer therapy.
- Future Development Potential: The CEO of Kairos Pharma noted that the emerging clinical data supports the potential to extend disease control, offering new hope for patients facing treatment resistance and further advancing the company's strategic development in the biopharmaceutical sector.
See More
Kairos Pharma to Hold Annual Shareholders Meeting Virtually
- Annual Meeting Announcement: Kairos Pharma, Ltd. has announced that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on June 29, 2026, with meeting materials to be mailed to shareholders post-filing with the SEC, ensuring compliance and transparency.
- Audit Report Emphasis: The financial statements included in the Annual Report for the year ended December 31, 2025, contain an audit report from an Independent Registered Public Accounting Firm, emphasizing that the statements were prepared under the assumption of the company's ongoing viability, reflecting confidence in future operations.
- Clinical Trial Developments: The company's lead candidate, ENV105, is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, aimed at addressing significant unmet medical needs, showcasing the company's innovative potential in oncology therapeutics.
- Cautionary Forward-Looking Statements: The press release includes cautionary forward-looking statements, alerting investors to potential risks and uncertainties, emphasizing that actual results may differ materially from expectations, reflecting the company's cautious approach to future developments.
See More
Schall Law Firm Investigates Kairos Pharma for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Kairos Pharma, focusing on potential violations of securities laws, including false or misleading statements that may affect investor rights.
- Investor Rights Protection: This investigation aims to protect investors, particularly those who have suffered losses due to the company's lack of transparency, by providing legal support to uphold their rights.
- Legal Consultation Services: Schall encourages affected shareholders to contact them for free legal consultations, helping investors understand their rights and possible legal avenues.
- Global Investor Representation: As a firm specializing in securities class action lawsuits and shareholder rights litigation, Schall Law Firm represents investors worldwide, committed to safeguarding their legitimate interests.
See More
Kairos Pharma Acquires CL-273 to Expand Oncology Pipeline
- Significant Market Opportunity: Kairos Pharma's acquisition of CL-273 targets a projected $16.2 billion EGFR-mutant lung cancer market by 2026, indicating a strategic positioning in the rapidly growing oncology therapeutics sector.
- Innovative Technical Advantage: CL-273 is an AI-designed pan-EGFR inhibitor specifically engineered for EGFR-mutant non-small cell lung cancer, expected to become a best-in-class asset addressing the urgent need for therapies against resistant mutations.
- Strengthened Partnerships: The collaboration with Celyn Therapeutics, backed by OrbiMed, enhances Kairos Pharma's research capabilities and is anticipated to accelerate the clinical development timeline for new therapies.
- Leadership Confidence: CEO John Yu stated that this acquisition is expected to be value-accretive, reflecting Kairos Pharma's long-term commitment and competitive edge in the oncology market.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Kairos Pharma to Acquire Oncology Assets from Celyn Therapeutics
- Acquisition Agreement: Kairos Pharma Ltd. announced the signing of a term sheet to acquire two clinical oncology assets from Celyn Therapeutics, specifically CL-273 and CL-741, aimed at addressing non-small cell lung cancer (NSCLC), one of the most prevalent and challenging cancers globally.
- Significant Market Potential: The market for kinase inhibitors in cancer treatment is projected to reach $60.7 billion by 2025, with EGFR inhibitors accounting for 32.5%, while CL-273 targets the EGFR-mutated lung cancer segment, expected to be valued at $16.2 billion by 2026, indicating substantial market opportunities.
- Innovative Treatment Strategy: Kairos aims to combine a pan-EGFR inhibitor with a c-MET inhibitor to overcome drug resistance in NSCLC, deepening tumor responses and extending progression-free survival, a strategy that aligns with AstraZeneca's SAVANNAH trial, underscoring its scientific rationale.
- Utilization of Clinical Infrastructure: CEO John Yu stated that if the acquisition is completed, it would significantly expand the company's pipeline and leverage the clinical infrastructure at Cedars-Sinai Medical Center to accelerate Phase 1 and Phase 2 studies, further solidifying its competitive position in the multi-billion-dollar lung cancer market.
See More
Kairos Pharma Wins 2025 Clinical Trials Arena R&D Award for Advanced Prostate Cancer
- Award Recognition: Kairos Pharma has been awarded the 2025 Clinical Trials Arena R&D Award for its innovative therapy ENV-105 in metastatic castration-resistant prostate cancer, highlighting its leadership in cancer treatment.
- Clinical Trial Results: In the Phase 2 trial of ENV-105 combined with apalutamide, 86% of patients showed clinical benefit, with all responders remaining progression-free for at least four months and some beyond one year, indicating the therapy's potential in patients with limited options.
- Targeted Therapy Strategy: ENV-105, as the first CD105-targeting monoclonal antibody, aims to overcome resistance following standard hormone treatments, emphasizing Kairos Pharma's innovative approach and scientific rigor in cancer therapy.
- Future Development Potential: The CEO of Kairos Pharma noted that the emerging clinical data supports the potential to extend disease control, offering new hope for patients facing treatment resistance and further advancing the company's strategic development in the biopharmaceutical sector.
See More
